MCMaria Soledad Cortina

Maria Soledad Cortina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maria Soledad Cortina has a total of 123 co-authors. Here are the top co-authors by number of shared publications:

  • Jose de la Cruz

    Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, Illinois, USA

    11 shared publications
  • Faris I. Karas

    Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL; and

    6 shared publications
  • Joel Sugar

    Department of Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, University of Illinois at Chicago, Chicago, IL

    4 shared publications
  • Jose de la Cruz

    UIC Department of Ophthalmology and Visual Sciences, Chicago, IL, USA

    4 shared publications
  • Ali R. Djalilian

    Department of Ophthalmology, Illinois Eye and Ear Infirmary, University of Illinois, Chicago, IL; and

    3 shared publications
  • Ali R. Djalilian

    Department of Ophthalmology and Visual Sciences, University of Illinois Chicago, Chicago, IL 60612, USA

    3 shared publications

Latest Publications

  • Severe Dupilumab-Associated Ocular Surface Disease: Multicenter Experience and Management Considerations

    by Allison Kufta, Syeda Zainab Kazmi, Seyyedehfatemeh Ghalibafan, Jeonghyun Kwon, Rishi Sharma, Josh Sun, Lisa M. Nijm, Elmer Y. Tu, Maria S. Cortina, Asim V. Farooq, et al.

    Purpose: To evaluate severe dupilumab-associated ocular surface disease (DAOSD) and identify clinical features, risk factors, and outcomes associated with delayed ophthalmologic referral. Methods: A multicenter retrospective case series of 13 patients (26 eyes) with severe DAOSD presenting to tertiary centers between January 2014 and April 2026 was conducted. Clinical findings were analyzed alongside a focused review of current evidence on pathophysiology, diagnosis, and management. Results: Initial ocular symptoms were frequently mild and nonspecific, most commonly redness and pruritus (13/13, 100%), followed by blurred vision with tearing (3/13, 23.1%), eye pain (2/13, 15.4%), and mucoid discharge (2/13, 15.4%), contributing to delayed referral. Symptom onset ranged from 0 to 37 months after dupilumab initiation (mean 11.7 months). At presentation, advanced disease manifestations included limbitis (3/13, 23.1%), conjunctivalization with corneal neovascularization (3/13, 23.1%), limbal stem cell deficiency (2/13, 15.4%), and cicatricial conjunctivitis (1/13, 7.7%). Preexisting atopic ocular disease was present in 6/13 patients (46.2%). Management included lubrication, topical corticosteroids, calcineurin inhibitors, and scleral lenses. Dupilumab was discontinued in 7/13 patients (53.8%). Clinical stabilization was achieved in 12/13 patients (92.3%) over a mean follow-up of 21.4 ± 20.3 months. Conclusions: Severe DAOSD may be underrecognized, as mild early symptoms can delay referral and allow progression to advanced, vision-threatening complications. Preexisting ocular surface disease identifies a high-risk subgroup. Early ophthalmologic evaluation and timely referral are essential to prevent irreversible ocular surface damage and vision loss.

  • Surgical applications of expanded polytetrafluoroethylene in ophthalmology: A review

    by Raul E. Ruiz-Lozano, Amanda K. Bicket, Ian Pitha, Nambi Nallasamy, Maria S. Cortina, Jose de la Cruz, Anitha Venugopal

  • Open Access

    Recurrent retroprosthetic membranes in Boston Keratoprosthesis Type I: Incidence, risk factors, and complications

    by Katherine G. Chen, Taylor W. Starnes, Sasha Kravets, Shanta Ghosh, Jose de la Cruz, Maria S. Cortina

  • Retroprosthetic Membrane Is Associated With Subsequent Development of de Novo Angle Closure in Eyes With Boston Keratoprosthesis

    by Faris I. Karas, Andrea C. Arteaga, Carmen Somavilla, Imane Tarib, Maria S. Cortina

    Purpose: Boston keratoprosthesis (KPro) is a widely used treatment for corneal diseases unsuitable for traditional keratoplasty. Postoperative complications, notably retroprosthetic membrane (RPM) formation and secondary glaucoma, significantly affect patient outcomes. Anterior segment optical coherence tomography (AS-OCT) enables precise visualization of KPro-related complications, such as angle closure and RPM formation. This study aimed to investigate the association between RPM formation and de novo angle closure in eyes with Boston KPro. Methods: A retrospective analysis of patients who underwent Boston KPro type 1 implantation was conducted. Patients with preoperative angles documented by AS-OCT and a minimum 1-year follow-up with serial AS-OCT imaging were included. Demographic data, surgical details, visual acuity, intraocular pressure, and complications were recorded. The presence of RPM and angle closure was assessed clinically and via AS-OCT. Results: This study included 18 eyes from 18 patients who underwent KPro implantation with a follow-up period averaging 4.7 years. Preoperative visual acuity was poor (20/400 or worse) in all eyes, with an improvement in 78% of cases to 20/200 or better postoperatively. Complications included angle closure in 61% of eyes, with a significant association between retroprosthetic membrane (RPM) formation and angle closure ( P = 0.0012). De novo glaucoma developed in 4 eyes, primarily associated with RPM and angle closure, and was managed medically. Conclusions: This study highlights a significant association between RPM formation and de novo angle closure in eyes with Boston KPro. Our study findings strongly suggest that RPM formation plays a role in inducing angle closure, contributing to glaucoma development, and is the first study to provide AS-OCT evidence of potential causality. Understanding these associations can improve patient care and outcomes after KPro implantation. Strategies aimed at reducing RPM formation could potentially mitigate other KPro-related complications, including angle closure and de novo glaucoma.


  • Open Access

    Neurotrophic keratopathy: Update in diagnosis and management

    by Carlos Segundo Font, Maria Soledad Cortina

    The cornea is the most densely sensory innervated tissue in the body. Sensory corneal nerves are essential to maintain ocular surface homeostasis and are involved in the blink reflex, tear production, and the release of trophic factors that are key in the wound healing process. Compromise of corneal sensory nerves leads to neurotrophic keratopathy (NK), an uncommon degenerative disorder that may lead to corneal epithelial breakdown, ulceration, corneal opacification, and even perforation. Management of this condition is difficult and visual disability often ensues in affected patients. While treatment has been traditionally focused in promoting epithelial healing, the past decade has seen a breakthrough in new medical and surgical therapies geared toward promoting corneal reinnervation. This review presents a comprehensive update on NK, focusing on current as well as potential new strategies for its diagnosis and management.


  • Long-Term Outcomes of Pediatric Keratoplasty at a Tertiary Care Center

    by Shivani P. Msj Majmudar, Priyanka Chhadva, Elmer Y. Tu, Ali R. Djalilian, Jose de la Cruz, Maria Soledad Cortina

    Purpose: To report the indications, postoperative visual outcomes, and long-term graft survival of primary pediatric keratoplasties performed at a single tertiary care center. Methods: We conducted a retrospective review of pediatric patients (16 years and younger) who underwent surgical intervention for corneal opacity at a tertiary care center to evaluate long-term graft survival and visual rehabilitation. Results: Seventy-three eyes of 46 patients met inclusion criteria. The mean patient age at the time of transplantation was 7.44 years (range, 5 months–15.72 years), and the average follow-up time was 5.82 years. Forty eyes (56%) had graft failure occurring at a mean time of 16.33 months (range, 27 days–12.58 years), of which 25 eyes (62.5%) underwent repeat keratoplasty. Cumulative graft survival probabilities at 1, 3, 5, and 7 years after keratoplasty were 60%, 55%, 44%, and 44%, respectively. Cox proportional hazards regression analysis showed Black ethnicity [hazard ratio (HR) = 4.72; confidence interval (CI), 1.16–19.23], mixed/other ethnicity (HR = 6.67, CI, 1.58–28.16), and keratoplasty in combination with another procedure (HR = 2.88; CI, 1.35–6.15) as significant risk factors of graft failure. 47 eyes (64%) achieved ambulatory vision (20/800 or better) at the last follow-up. Age younger than 5 years at time of keratoplasty was associated with better visual outcomes in patients with congenital disease (P = 0.0017). Conclusions: Pediatric keratoplasty has a high rate of graft failure but can achieve ambulatory vision in >60% of patients. Keratoplasty outcomes are improved in non-Hispanic, White patients and when the intervention is performed alone. Younger age at time of keratoplasty for congenital conditions improves the likelihood of overall visual rehabilitation.


  • Open Access

    Metalloproteinase-9 on the Ocular Surface of Patients With Implanted Boston Type 1 Keratoprosthesis

    by Andrea C. Arteaga, Margaret C. Bs Weiss, Raiza Perez, María Soledad Cortina

    Purpose: The aim of this study was to characterize the presence of ocular surface inflammation, using matrix metalloproteinase-9 (MMP-9) as a marker, on the ocular surface of eyes with implanted Boston keratoprosthesis type 1 (KPro). Methods: Patients with implanted KPro at a single tertiary center were recruited to assess ocular inflammation. MMP-9 was measured using the InflammaDry test in both eyes of each patient. The non-KPro eye served as the control. Rate of positivity of MMP-9 was compared between groups. Possible associations between ocular surface inflammation and the development of postoperative complications were evaluated using univariate statistical analysis. Results: Fifty eyes from 25 patients were included. The mean age was 50 years. Noninflammatory indications for KPro were predominant among patients. Eighty-eight percent of KPro eyes had a positive test for MMP-9 while only 25% of control eyes were positive (P < 001). The most common complications were retroprosthetic membrane, epithelial defects, and sterile corneal melt. The presence of a strong positive result was associated with a higher frequency of complications (80% of eyes) compared with a faint positive test (54%) and a negative test (33%). Conclusions: The KPro device seems to increase MMP-9 levels on the ocular surface. High MMP-9 levels may be associated with higher risk of complications. MMP-9 testing can be useful to assess subclinical ocular surface inflammation with a potential role in the postoperative care of patients with KPro.


  • Open Access

    Boston type I keratoprosthesis

    by Karen Hu, Imane Tarib, Maria Soledad Cortina

    Review Article Boston type I keratoprosthesis Karen Hu, Imane Tarib, Maria Soledad Cortina